BioLineRx licenses inflammation treatment

By JERUSALEM POST BUSINESS STAFF
March 22, 2007 06:53

BioLineRx Ltd., said Wednesday it signed a worldwide exclusive license agreement with Yissum Research Development Co. of Hebrew University and Ramot at Tel Aviv University Ltd., the technology transfer company of TAU, for the development and commercialization of BL-4020, a novel peptide for the treatment of inflammatory diseases. Financial terms of the license were not disclosed.


Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS

Israel Weather
  • 15 - 30
    Beer Sheva
    18 - 25
    Tel Aviv - Yafo
  • 15 - 26
    Jerusalem
    16 - 25
    Haifa
  • 20 - 36
    Elat
    17 - 32
    Tiberias